Colorado board makes first-in-nation transfer, units cost restrict on Amgen drug
In a first-in-the-nation transfer, a Colorado panel has voted to restrict what well being plans within the state pays for a pricey arthritis remedy, a step which will encourage different states to pursue comparable methods to comprise spending on prescription medicines.
The landmark vote by the Colorado Prescription Drug Affordability Board creates an higher cost restrict for the broadly prescribed Enbrel medicine, which is a blockbuster remedy bought by Amgen. As a sensible matter, the choice establishes a cost ceiling for presidency companies and industrial plans that present medical health insurance for state residents.
The restrict was set at $600 per unit, which can be the present most truthful worth that’s set to enter impact within the Medicare program in January. This works out to roughly $30,350 a yr per individual, in contrast with roughly $53,000 that the typical insurance coverage plan within the state paid per individual in 2023, in keeping with state claims database.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
